Biotech 365

Main menu

Skip to primary content
Skip to secondary content
  • Biotech 365
    • Contact
    • Offers
  • Biotech Companies
  • Database researchers
    • BioLeads
  • BioMarketplace
  • Biotech Jobs
  • Biopharma News

Tag Archives: Annick Schwebig

Cellectis – gene-editing

Posted on 2015-03-18 by Biotech365

Cellectis is a biotech company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART).

Cellectis – gene-editing

Cellectis

Continue reading →

Posted in Biotech Companies, Biotech Companies France | Tagged Acute lymphoblastic leukemia, Acute myeloid leukemia, adoptive immunotherapies, adoptive immunotherapy, Alain Godard, ALCLS, ALL, allogeneic T cells engineered, AML, André Choulika, Annick Schwebig, autologous adoptive immunotherapies, autologous adoptive immunotherapy, B cells malignancies, CAR, CAR-engineered cell, Cellectis, Cellectis - gene-editing, Chimeric Antigen Receptor, Chronic lymphocytic leukemia, CLL, David Sourdive, electroporation PulseAgile technology, engineered nuclease, engineered nucleases, gene edited engineered CAR-T cell, gene edited engineered CAR-T cells, gene edited engineered T cell, gene engineering, gene-editing, genome engineering, glioblastoma, immunotherapies, immunotherapy, Laurent Arthaud, leukemia, Mathieu Simon, meganuclease, meganucleases, Multiple myeloma, non-small-cell lung cancer, pancreatic cancer, Philippe Duchateau, Pierre Bastid, PulseAgile, T cells, T-cell, TALEN, TALEN products, Thierry Moulin, UCART
Contact                       Offers                      
Proudly powered by WordPress